Rezolute Inc (RZLT)

Currency in USD
3.010
-0.130(-4.14%)
Real-time Data·
Earnings results expected in 6 days
RZLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.0053.130
52 wk Range
1.07011.457
Key Statistics
Prev. Close
3.14
Open
3.13
Day's Range
3.005-3.13
52 wk Range
1.07-11.457
Volume
361.46K
Average Volume (3m)
2.41M
1-Year Change
-13.0194%
Book Value / Share
1.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RZLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.125
Upside
+70.27%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Rezolute Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.125
(+70.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy5.00+65.56%-Maintain04/05/2026
Cantor Fitzgerald
Hold---Maintain25/03/2026
H.C. Wainwright
Buy5.00+65.56%-Maintain25/03/2026
Wedbush
Buy5.00+65.56%2.00Upgrade25/03/2026
Citizens
Hold---Maintain25/03/2026

Rezolute Inc SWOT Analysis


Pipeline Progress
Explore Rezolute's promising clinical trials for ersodetug in hyperinsulinism and RZ402 for diabetic macular edema, with key results expected in 2025-2026.
Financial Strength
Delve into Rezolute's robust financial position, with $118 million in cash and a strong current ratio, supporting ongoing clinical programs.
Market Opportunities
Learn about Rezolute's potential in niche markets, including congenital hyperinsulinism and diabetic macular edema, with oral administration as a key advantage.
Analyst Outlook
Discover varied analyst perspectives on Rezolute, with price targets ranging from $7 to $9, reflecting the company's growth potential in metabolic diseases.
Read full SWOT analysis

Earnings

Latest Release
12/02/2026
EPS / Forecast
-0.22 / -0.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare RZLT to Peers and Sector

Metrics to compare
RZLT
Peers
Sector
Relationship
P/E Ratio
−3.8x−3.1x−0.5x
PEG Ratio
−0.17−0.050.00
Price/Book
2.5x5.5x2.6x
Price / LTM Sales
-19.7x3.2x
Upside (Analyst Target)
59.2%78.4%48.3%
Fair Value Upside
Unlock0.5%5.6%Unlock

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
30.24M29.11%94.94M
Other Institutional Investors
69.65M67.05%218.69M
Public Companies & Retail Investors
3.99M3.84%12.53M
Total
103.87M100.00%326.16M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Federated Hermes, Inc.15.92%16,534,71251,919
RA Capital Management, L.P.8.84%9,180,00028,825

People Also Watch

5.710
UGRO
-2.39%
2.183
BIAF
+10.26%
2.1856
ELAB
+2.61%
11.79
PHAT
-6.99%
33.725
CUE
-0.75%

FAQ

What Is the Rezolute (NASDAQ: RZLT) Share Price Today?

The Rezolute stock price today is 3.010 USD.

What Stock Exchange Does Rezolute (RZLT) Trade On?

Rezolute is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Rezolute?

The stock symbol (also called a 'ticker') for Rezolute is "RZLT."

What Is the Current Rezolute Market Capitalisation?

As of today, Rezolute (NASDAQ: RZLT) market cap is 326.160M USD.

What Is Rezolute's (RZLT) Earnings Per Share (TTM)?

The Rezolute EPS is currently -0.908 (Trailing Twelve Months).

When Is the Next Rezolute Earnings Date?

Rezolute's next earnings report will be released on 13/05/2026.

Is RZLT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Rezolute moving averages and other technical indicators, the daily buy/sell signal for RZLT stock is Strong Sell.

How Many Times Has Rezolute Stock Split?

Rezolute has split 3 times. (See the RZLT stock split history page for full effective split date and price information.)

How Many Employees Does Rezolute Have?

Rezolute has 75 employees, based on their latest Companies House report.

What is the current trading status of Rezolute (NASDAQ: RZLT)?

As of 07/05/2026, Rezolute (RZLT) is trading at a share price of 3.010 USD, with a previous close of 3.140 USD. The stock has fluctuated within a day range of 3.005 USD to 3.130 USD, while its 52-week range spans from 1.070 USD to 11.457 USD.

What Is Rezolute (RZLT) Price Target According to Analysts?

The average 12-month price target for Rezolute is 5.125 USD, with a high estimate of 6 USD and a low estimate of 4 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +70.27% Upside potential.

What Is the RZLT Premarket Price?

RZLT's last pre-market stock price is 3.124 USD. The pre-market share volume is 3,420.000, and the stock has decreased by -0.016, or -0.510%.

What Is the RZLT After Hours Price?

RZLT's last after hours stock price is 3.128 USD, the stock has decreased by -0.012, or -0.380%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.